无功能性垂体腺瘤初始手术后的管理:监测、放疗还是手术?
该回顾性研究纳入2007至2018年随访的256例无功能性垂体腺瘤患者,评估初始手术后辅助放疗、监测及复发后再次手术或挽救性放疗的疗效。结果显示辅助放疗与挽救性放疗的5年无进展生存相似(90% vs 97%,p=0.62),作者认为「等待观察」可作为选项,复发或进展时推荐挽救性放疗以避免第二次手术。
要点
- 辅助放疗与挽救性放疗的5年无进展生存相似(90% vs 97%,p=0.62)。
- 单纯手术与手术加辅助放疗的无进展生存显著不同(HR=0.24,p<0.0005)。
- 作者推荐复发或进展时行挽救性放疗以避免第二次手术。
核心结论
- 对于因无功能性垂体腺瘤接受手术的患者,「等待观察」应作为一项选择,因为辅助放疗并不优于挽救性放疗。
- 作者建议在复发或进展时行挽救性放疗,以避免第二次手术。
研究设计与样本
- 回顾性研究,纳入2007至2018年间随访的256例无功能性垂体腺瘤患者。
- 初始手术时平均年龄55岁[18-86],术后MRI发现87%的患者有残留肿瘤,平均随访12.1年[0.8-42.7]。
主要发现
- 初始手术后,40例接受辅助放疗;单纯手术组与手术加辅助放疗组在5年、10年和15年的无进展生存分别为77%、58%、40%与84%、78%、78%(HR=0.24[0-0.53],p<0.0005)。
- 总体而言,在第一、第二或第三次手术后,69例接受辅助放疗,41例接受挽救性放疗;辅助放疗与挽救性放疗的5年无进展生存相似(90% vs 97%,p=0.62)。
- 第二次手术后,62%和71%的患者分别在2年和5年后接受放疗。
- 第二或第三次手术后,促肾上腺皮质激素和促甲状腺激素缺乏的风险分别为38%和59%;放疗后分别为40%和73%。
- 4例患者发生脑肿瘤:1例脑膜瘤在初始手术时已存在;放疗后,1例神经鞘瘤在5年时出现,1例胶质母细胞瘤在13年时出现,1例脑膜瘤在20年时出现。
临床怎么用
- 作者认为「等待观察」应作为无功能性垂体腺瘤初始手术后的选项之一。
- 作者建议在复发或进展时行挽救性放疗,以避免第二次手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at the multidisciplinary tumor board. The purpose of this study was to evaluate the therapeutic outcome for each option. METHODS: The records of 256 patients followed with NFPA between 2007 and 2018 were retrospectively reviewed. Mean age at initial surgery was 55 years [18-86]. Post-operative MRI found a residual tumor in 87% of patients. Mean follow-up was 12.1 years [0.8-42.7]. RESULTS: After initial surgery, 40 patients had adjuvant radiotherapy. At 5, 10 and 15 years progression-free survival (PFS) was significantly different after surgery alone (77%, 58% and 40%) compared to surgery and adjuvant radiotherapy (84%, 78% and 78%) (HR = 0.24 [0-0.53] p < 0.0005). Overall, after first, second or third surgical operation, 69 patients had adjuvant radiotherapy and 41 salvage radiotherapy. Five-year PFS was similar for adjuvant (90%) and salvage radiotherapy (97%) (p = 0.62). After a second surgical operation, 62% and 71% of patients were irradiated after 2 and 5 years respectively. The risk of corticotropic and thyrotropic deficiency rates were 38% and 59% after second or third surgical operation and 40% and 73% after radiotherapy. Brain tumors occurred in 4 patients: 1 meningioma present at initial surgery, and after radiotherapy, 1 neurinoma which appeared at 5 years, 1 glioblastoma at 13 years and 1 meningioma at 20 years. CONCLUSION: Among patients treated by surgery for NFPA, a "wait-and-see" attitude should be an option since adjuvant radiotherapy is not superior to salvage radiotherapy. However, in case of recurrence or progression, the authors recommended delivery of salvage radiotherapy to avoid a second surgical operation.
引用
- Charleux T, Vendrely V, Huchet A, et al. Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery? Radiat Oncol. 2022. PMID: 36229880. doi:10.1186/s13014-022-02133-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。